{"denoms":[{"counts":[{"groupId":"BG000","value":"301"},{"groupId":"BG001","value":"300"},{"groupId":"BG002","value":"601"}],"units":"Participants"}],"groups":[{"description":"Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.\n\n3-Dimensional Conformal Radiation Therapy: Undergo pelvic radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo pelvic radiation therapy\n\nInternal Radiation Therapy: Undergo vaginal cuff brachytherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"BG000","title":"Arm I (Pelvic Radiation Therapy)"},{"description":"Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nInternal Radiation Therapy: Undergo vaginal cuff brachytherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"BG001","title":"Arm II (Brachytherapy, Paclitaxel, Carboplatin)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"38"}]}],"title":"<50 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"167"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"137"},{"groupId":"BG002","value":"252"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"144"}]}],"title":">=70 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"301"},{"groupId":"BG001","value":"300"},{"groupId":"BG002","value":"601"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"106"}]}],"title":"Endometrioid, grade 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"212"}]}],"title":"Endometrioid, grade 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"126"}]}],"title":"Endometrioid, grade 3 or not graded"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"88"}]}],"title":"Serous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"28"}]}],"title":"Clear Cell"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"31"}]}],"title":"Mixed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}]}],"title":"Other"}],"description":"Grade 1 endometrioid endometrial cancers are well differentiated. Grade 2 tumors are moderately differentiated. Grade 3 tumors are poorly differentiated. Lower grades have a higher relapse free survival rate..","paramType":"COUNT_OF_PARTICIPANTS","title":"Cell Type","unitOfMeasure":"Participants"}],"populationDescription":"Enrolled patients"}